Generic vs brand originator alendronate: Analysis of persistence and compliance in five local healthcare units in the lombardy region of Italy

Giorgio L. Colombo, Carlo Maurizio Montecucco

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The appearance of off-patent generic drugs in the world pharmaceutical market is a highly interesting fact from the socio-economic point of view. However, the scientific documentation supporting the potential clinical and economic benefits of a growing use of off-patent alendronate generic in clinical practice seems to be limited in Italy as yet. Patients and methods. Comparing differences in persistence and compliance between off-patent generic alendronate and off-patent brand alendronate originator (Fosamax ® ) in real clinical practice. The retrospective analysis was carried out by using the administrative databases of five Local Healthcare Units (ASL - Aziende Sanitarie Locali) in the Lombardy Region, in Italy. Results. The selected sample of 5 ASLs included 20,711 patients; the average age was 73 years, with no difference between the two groups. After 34 months of observation, the persistence and compliance were no statistically different between off-patent generic alendronate vs off-patent brand alendronate. Data on days in persistence varied between 316 (Brand) vs 362 (Generic). Patients' compliance varied in average between 0.70 (Brand) and 0.72 for generic group. Conclusions. Off-patent generic drugs appear to be a therapy option of choice in Italy as well, both for the National Health Service and for citizens. Off-patent generic drugs can bring about an increased efficiency in health systems and increase the percentage of population benefitting from a medical care plan.

Original languageEnglish
Pages (from-to)195-198
Number of pages4
JournalClinical Cases in Mineral and Bone Metabolism
Volume10
Issue number3
Publication statusPublished - Sep 2013

Fingerprint

Alendronate
Italy
Compliance
Generic Drugs
Delivery of Health Care
Economics
National Health Programs
Patient Compliance
Documentation
Observation
Databases
Health
Pharmaceutical Preparations
Population

Keywords

  • Alendronate
  • Compliance
  • Cost analysis
  • Generic drug
  • Persistence

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine

Cite this

@article{a2ab85c7d4b94cbfad8ca19ac3c3442c,
title = "Generic vs brand originator alendronate: Analysis of persistence and compliance in five local healthcare units in the lombardy region of Italy",
abstract = "The appearance of off-patent generic drugs in the world pharmaceutical market is a highly interesting fact from the socio-economic point of view. However, the scientific documentation supporting the potential clinical and economic benefits of a growing use of off-patent alendronate generic in clinical practice seems to be limited in Italy as yet. Patients and methods. Comparing differences in persistence and compliance between off-patent generic alendronate and off-patent brand alendronate originator (Fosamax {\circledR} ) in real clinical practice. The retrospective analysis was carried out by using the administrative databases of five Local Healthcare Units (ASL - Aziende Sanitarie Locali) in the Lombardy Region, in Italy. Results. The selected sample of 5 ASLs included 20,711 patients; the average age was 73 years, with no difference between the two groups. After 34 months of observation, the persistence and compliance were no statistically different between off-patent generic alendronate vs off-patent brand alendronate. Data on days in persistence varied between 316 (Brand) vs 362 (Generic). Patients' compliance varied in average between 0.70 (Brand) and 0.72 for generic group. Conclusions. Off-patent generic drugs appear to be a therapy option of choice in Italy as well, both for the National Health Service and for citizens. Off-patent generic drugs can bring about an increased efficiency in health systems and increase the percentage of population benefitting from a medical care plan.",
keywords = "Alendronate, Compliance, Cost analysis, Generic drug, Persistence",
author = "Colombo, {Giorgio L.} and Montecucco, {Carlo Maurizio}",
year = "2013",
month = "9",
language = "English",
volume = "10",
pages = "195--198",
journal = "Clinical Cases in Mineral and Bone Metabolism",
issn = "1724-8914",
publisher = "CIC Edizioni Internazionali s.r.l.",
number = "3",

}

TY - JOUR

T1 - Generic vs brand originator alendronate

T2 - Analysis of persistence and compliance in five local healthcare units in the lombardy region of Italy

AU - Colombo, Giorgio L.

AU - Montecucco, Carlo Maurizio

PY - 2013/9

Y1 - 2013/9

N2 - The appearance of off-patent generic drugs in the world pharmaceutical market is a highly interesting fact from the socio-economic point of view. However, the scientific documentation supporting the potential clinical and economic benefits of a growing use of off-patent alendronate generic in clinical practice seems to be limited in Italy as yet. Patients and methods. Comparing differences in persistence and compliance between off-patent generic alendronate and off-patent brand alendronate originator (Fosamax ® ) in real clinical practice. The retrospective analysis was carried out by using the administrative databases of five Local Healthcare Units (ASL - Aziende Sanitarie Locali) in the Lombardy Region, in Italy. Results. The selected sample of 5 ASLs included 20,711 patients; the average age was 73 years, with no difference between the two groups. After 34 months of observation, the persistence and compliance were no statistically different between off-patent generic alendronate vs off-patent brand alendronate. Data on days in persistence varied between 316 (Brand) vs 362 (Generic). Patients' compliance varied in average between 0.70 (Brand) and 0.72 for generic group. Conclusions. Off-patent generic drugs appear to be a therapy option of choice in Italy as well, both for the National Health Service and for citizens. Off-patent generic drugs can bring about an increased efficiency in health systems and increase the percentage of population benefitting from a medical care plan.

AB - The appearance of off-patent generic drugs in the world pharmaceutical market is a highly interesting fact from the socio-economic point of view. However, the scientific documentation supporting the potential clinical and economic benefits of a growing use of off-patent alendronate generic in clinical practice seems to be limited in Italy as yet. Patients and methods. Comparing differences in persistence and compliance between off-patent generic alendronate and off-patent brand alendronate originator (Fosamax ® ) in real clinical practice. The retrospective analysis was carried out by using the administrative databases of five Local Healthcare Units (ASL - Aziende Sanitarie Locali) in the Lombardy Region, in Italy. Results. The selected sample of 5 ASLs included 20,711 patients; the average age was 73 years, with no difference between the two groups. After 34 months of observation, the persistence and compliance were no statistically different between off-patent generic alendronate vs off-patent brand alendronate. Data on days in persistence varied between 316 (Brand) vs 362 (Generic). Patients' compliance varied in average between 0.70 (Brand) and 0.72 for generic group. Conclusions. Off-patent generic drugs appear to be a therapy option of choice in Italy as well, both for the National Health Service and for citizens. Off-patent generic drugs can bring about an increased efficiency in health systems and increase the percentage of population benefitting from a medical care plan.

KW - Alendronate

KW - Compliance

KW - Cost analysis

KW - Generic drug

KW - Persistence

UR - http://www.scopus.com/inward/record.url?scp=84894135448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84894135448&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84894135448

VL - 10

SP - 195

EP - 198

JO - Clinical Cases in Mineral and Bone Metabolism

JF - Clinical Cases in Mineral and Bone Metabolism

SN - 1724-8914

IS - 3

ER -